血清可溶性晚期糖基化终产物受体水平与系统性红斑狼疮疾病活动度的相关性

Association between Serum Levels of Soluble Receptor for Advanced Glycation End-products and Disease Activity of Systemic Lupus Erythematosus

目的探讨可溶性晚期糖基化终产物受体(soluble receptor for advanced glycation end-products,sRAGE)在系统性红斑狼疮(systemic lupus erythematosus,SLE)疾病活动度评价中的价值。方法收集2013年6月至2014年6月郑州大学第一附属医院SLE患者的临床及流行病学资料,观察血清sRAGE浓度与SLE疾病活动度的相关性。结果 SLE组、非活动SLE组、活动SLE组和健康对照组sRAGE浓度分别为(1 060.16±762.59)、(912.06±759.98)、(1 232.96±736.16)、(1 300.42±466.01)pgml;SLE组与健康对照组sRAGE浓度差异有统计学意义(Z=-2.891,P=0.004),非活动SLE组、活动SLE组与健康对照组sRAGE浓度差异有统计学意义(χ2=17.999,P=0.000)。血清sRAGE浓度在SLE疾病活动指数≥10(Z=-3.052,P=0.002)和抗双链-DNA抗体滴度≥100(Z=-2.276,P=0.023)者中更高。血清sRAGE浓度与SLE疾病活动指数≥10(r=0.373,P=0.000)呈正相关。结论通过检测血清sRAGE浓度能够评价SLE患者疾病活动度,为制定临床治疗方案提供依据。

Objective The aim of our study was to investigate the value of serum soluble receptor for advanced glycation （sRAGE）levels in the estimation of disease activity of systemic lupus erythematosus （SLE）. Methods 104 patients who suffered from SLE and who had been treated in our hospital from June 2013 to June 2014 were included into our study.Clinical and epidemiological data were collected.Results The concentration of sRAGE in the SLE group,the non-active SLE group,active SLE group,and the control group were （1 060.16 ±762.59）,（912.06 ±759.98）,（1 232.96 ±736.16）,and（1 300.42 ±466.01） pg/ml respectively,so the difference was statistically significant （Z = -2.891,P =0.004 ）.The difference was statistically significant among the non-active SLE group,active SLE group,and the control group （χ2 =17.999,P =0.000）.There was higher serum sRAGE levels in patients whose SLE disease＆amp;nbsp;activity index（SLEDAI）≥10 （Z =-3.052,P =0.002）and whose titer of anti-dsDNA antibody≥100 （Z =-2.276,P =0.023）,and there was positive correlation between serum sRAGE levels and SLEDAI≥10（r =0.373,P =0.000）,the difference was statistically significant.Conclusion We can evaluate disease activity of SLE by detecting the serum sRAGE levels,which may provide information to guide the treatment.